Drug Transparency Bill Stripped of Critical Provisions Ahead of Senate Vote

The Clear Labels Act was proposed to require prescription labels to disclose where drugs are manufactured so doctors, patients and researchers can trace products to specific factories. It was originally to include a unique facility identifier used by the FDA (a DUNS number) and take effect about a year after passage. Both of those provisions were removed in committee: the identifier was stripped and compliance was pushed to five years. Under the revised language labels would only need to show a “place of business” or factory address, which experts warn can be vague or point to a headquarters or importer's U.S. office rather than an overseas production site. ProPublica’s prior reporting showed unsafe conditions at some foreign generic plants and used DUNS numbers to connect thousands of drugs to specific facilities; reporters found that DUNS allowed direct facility linkage for 69% of labels, whereas plain addresses were often ambiguous.

Supporters framed the measure as a win for consumer safety, but critics - including former FDA inspectors, public-health researchers and supply-chain officers - call the changes a significant weakening that will make enforcement harder and preserve opacity. Lawmakers cited concerns about potential price effects and national security, and industry lobbying opposed stronger requirements. The Senate committee approved the watered-down bill with one dissent, and the full Senate will consider it; opponents argue the remaining language and long implementation window leave loopholes that undercut the law’s transparency purpose.